Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Literature DB >> 30796026

Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Abstract

Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.

Entities: Disease Species

Mesh：

Substances：

Year: 2019 PMID： 30796026 PMCID： PMC6634959 DOI： 10.1182/blood-2018-12-852376

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

34 in total

1. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

Authors: Renato Bassan; Orietta Spinelli; Elena Oldani; Tamara Intermesoli; Manuela Tosi; Barbara Peruta; Giuseppe Rossi; Erika Borlenghi; Enrico M Pogliani; Elisabetta Terruzzi; Pietro Fabris; Vincenzo Cassibba; Giorgio Lambertenghi-Deliliers; Agostino Cortelezzi; Alberto Bosi; Giacomo Gianfaldoni; Fabio Ciceri; Massimo Bernardi; Andrea Gallamini; Daniele Mattei; Eros Di Bona; Claudio Romani; Anna Maria Scattolin; Tiziano Barbui; Alessandro Rambaldi
Journal: Blood Date: 2009-01-13 Impact factor: 22.113

2. Toward victory in adult ALL: blinatumomab joins in.

Authors: Renato Bassan
Journal: Blood Date: 2012-12-20 Impact factor: 22.113

3. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.

Authors: Elias Jabbour; Johannes Düll; Musa Yilmaz; Joseph D Khoury; Farhad Ravandi; Nitin Jain; Hermann Einsele; Guillermo Garcia-Manero; Marina Konopleva; Nicholas J Short; Philip A Thompson; William Wierda; Naval Daver; Jorge Cortes; Susan O'brien; Hagop Kantarjian; Max S Topp
Journal: Am J Hematol Date: 2017-12-23 Impact factor: 10.047

4. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors: Arend von Stackelberg; Franco Locatelli; Gerhard Zugmaier; Rupert Handgretinger; Tanya M Trippett; Carmelo Rizzari; Peter Bader; Maureen M O'Brien; Benoît Brethon; Deepa Bhojwani; Paul Gerhardt Schlegel; Arndt Borkhardt; Susan R Rheingold; Todd Michael Cooper; Christian M Zwaan; Phillip Barnette; Chiara Messina; Gérard Michel; Steven G DuBois; Kuolung Hu; Min Zhu; James A Whitlock; Lia Gore
Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544

5. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

Authors: Giovanni Martinelli; Nicolas Boissel; Patrice Chevallier; Oliver Ottmann; Nicola Gökbuget; Max S Topp; Adele K Fielding; Alessandro Rambaldi; Ellen K Ritchie; Cristina Papayannidis; Lulu Ren Sterling; Jonathan Benjamin; Anthony Stein
Journal: J Clin Oncol Date: 2017-03-29 Impact factor: 44.544

6. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.

Authors: Annabelle Zoghbi; Udo Zur Stadt; Beate Winkler; Ingo Müller; Gabriele Escherich
Journal: Pediatr Blood Cancer Date: 2017-04-28 Impact factor: 3.167

7. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

Authors: Sébastien Maury; Sylvie Chevret; Xavier Thomas; Dominik Heim; Thibaut Leguay; Françoise Huguet; Patrice Chevallier; Mathilde Hunault; Nicolas Boissel; Martine Escoffre-Barbe; Urs Hess; Norbert Vey; Jean-Michel Pignon; Thorsten Braun; Jean-Pierre Marolleau; Jean-Yves Cahn; Yves Chalandon; Véronique Lhéritier; Kheira Beldjord; Marie C Béné; Norbert Ifrah; Hervé Dombret
Journal: N Engl J Med Date: 2016-09-15 Impact factor: 91.245

8. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

Authors: Kheira Beldjord; Sylvie Chevret; Vahid Asnafi; Françoise Huguet; Marie-Laure Boulland; Thibaut Leguay; Xavier Thomas; Jean-Michel Cayuela; Nathalie Grardel; Yves Chalandon; Nicolas Boissel; Beat Schaefer; Eric Delabesse; Hélène Cavé; Patrice Chevallier; Agnès Buzyn; Thierry Fest; Oumedaly Reman; Jean-Paul Vernant; Véronique Lhéritier; Marie C Béné; Marina Lafage; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret
Journal: Blood Date: 2014-04-16 Impact factor: 22.113

9. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors: Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal: N Engl J Med Date: 2016-06-12 Impact factor: 91.245

10. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.

Authors: C L Haddox; A A Mangaonkar; D Chen; M Shi; R He; J L Oliveira; M R Litzow; A Al-Kali; W J Hogan; M A Elliott
Journal: Blood Cancer J Date: 2017-09-15 Impact factor: 11.037

18 in total

Review 1. Bispecific antibodies in cancer immunotherapy.

Authors: Christoph Rader
Journal: Curr Opin Biotechnol Date: 2019-12-13 Impact factor: 9.740

2. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.

Authors: Rebecca L Goldstein; Ana Goyos; Chi-Ming Li; Petra Deegen; Pamela Bogner; Alexander Sternjak; Oliver Thomas; Matthias Klinger; Joachim Wahl; Matthias Friedrich; Benno Rattel; Edwin Lamas; Xiaoshan Min; Athena Sudom; Mozhgan Farshbaf; Angela Coxon; Mercedesz Balazs; Tara Arvedson
Journal: Blood Adv Date: 2020-09-08

3. Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?

Authors: Lori Muffly; Emily Curran
Journal: Hematology Am Soc Hematol Educ Program Date: 2019-12-06

4. Minimal residual disease and stem cell transplantation outcomes.

Authors: Jacqueline Cloos; Gert J Ossenkoppele; Richard Dillon
Journal: Hematology Am Soc Hematol Educ Program Date: 2019-12-06

5. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.

Authors: Lori Muffly; Vandana Sundaram; Connie Chen; Ilana Yurkiewicz; Eric Kuo; Sarah Burnash; Jay Y Spiegel; Sally Arai; Matthew J Frank; Laura J Johnston; Robert Lowsky; Everett H Meyer; Robert S Negrin; Andrew R Rezvani; Surbhi Sidana; Parveen Shiraz; Judith A Shizuru; Wen-Kai Weng; Michaela Liedtke; Hyma T Vempaty; David B Miklos
Journal: Blood Adv Date: 2021-08-24

6. Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase.

Authors: Shyam A Patel; Jacob R Bledsoe; Anne W Higgins; Lloyd Hutchinson; Jonathan M Gerber
Journal: JCO Precis Oncol Date: 2021-07-09

7. TCR β chain-directed bispecific antibodies for the treatment of T cell cancers.

Authors: Suman Paul; Alexander H Pearlman; Jacqueline Douglass; Brian J Mog; Emily Han-Chung Hsiue; Michael S Hwang; Sarah R DiNapoli; Maximilian F Konig; Patrick A Brown; Katharine M Wright; Surojit Sur; Sandra B Gabelli; Yana Li; Gabriel Ghiaur; Drew M Pardoll; Nickolas Papadopoulos; Chetan Bettegowda; Kenneth W Kinzler; Shibin Zhou; Bert Vogelstein
Journal: Sci Transl Med Date: 2021-03-01 Impact factor: 17.956

Review 8. Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats.

Authors: Brent A Williams; Arjun Law; Judit Hunyadkurti; Stephanie Desilets; Jeffrey V Leyton; Armand Keating
Journal: J Clin Med Date: 2019-08-20 Impact factor: 4.241

9. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1.

Authors: Meng Lv; Qian Jiang; Dao-Bin Zhou; Yu Hu; Dai-Hong Liu; De-Pei Wu; Jing-Bo Wang; Hao Jiang; Jing Wang; Ying-Jun Chang; Yu Wang; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal: J Hematol Oncol Date: 2020-05-15 Impact factor: 17.388

10. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo.

Authors: N N Parayath; S B Stephan; A L Koehne; P S Nelson; M T Stephan
Journal: Nat Commun Date: 2020-11-27 Impact factor: 14.919